News Release

Cleanascite™ Employed to Help Determine Role of Fatty Acids in Multiple Myeloma

MONMOUTH JUNCTION, NJ, June 14, 2023 -- Biotech Support Group reports on an article, describing the simplicity and efficiency of their lipid clearance sample preparation technology to help determine the role of fatty acids in the suppression of T cell function in the bone marrow microenvironment. The citation is:

Gudgeon, Nancy, et al. "Uptake of long-chain fatty acids from the bone marrow suppresses CD8+ T-cell metabolism and function in multiple myeloma." Blood Advances (2023).

T cells demonstrate impaired function in Multiple Myeloma (MM), but suppressive mechanisms in the bone marrow (BM) microenvironment remain poorly defined. In vitro modelling confirmed that uptake of bone marrow lipids suppresses CD8 + T function, which is impaired in autologous bone marrow plasma, but rescued by lipid removal. The article states “…to probe a role for lipids in this suppressive activity of BM plasma, they were depleted from BM samples (through the use of Cleanascite™) and compared with lipid-replete BM samples. Removal of BM lipids increased mitochondrial mass in control and MM BM CD8+ T cells (Figure 3E), accompanied by restoration of IFN-γ and TNF-α expression (Figure 3F-H)..”.

The authors conclude that CD8+ 38 T-cell function and mitochondrial mass decline in the bone marrow in multiple myeloma and are lower than in matched peripheral blood. These changes are linked to uptake of long-chain fatty acids and T-cell function and can be rescued by blockade of the lipid transporter FATP1.

“We now have over twenty references, showing that Cleanascite™ was used to help identify a characteristic feature of in vitro cell response. Unlike alternative lipid-depletion methods that use solvents, Cleanascite™ is an aqueous suspension product and so it is very compatible with cellular models of disease. This ultimately helps with investigations such as this, whereby endogenous lipids need to be stripped to determine their influence on cell response.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

To download whitepaper entitled “Cleanascite™ - Lipid Removal and Cell Response Applications”, visit:

https://www.biotechsupportgroup.com/v/vspfiles/templates/257/pdf/CleanasciteCellResponseReferenceApplications02212023.pdf

For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com.

For Business Development, contact: Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com